Clinical Trials of Adult Stem Cell Therapy for Peripheral Artery
                        Disease

Botham, Crystal M.; Bennett, William L.; Cooke, John P.

doi:10.14797/mdcj-9-4-201

Cited by 32 publications

(30 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Peripheral artery diseases often result from occlusive artery diseases, typically atherosclerosis. They share risk factors with coronary artery diseases including hyperlipidemia, diabetes mellitus, and hypertension . Chronic ischemia of peripheral tissues leads to serious conditions, including critical limb ischemia and amputation.…”

Section: Animal Studies and Clinical Trials Using Mscs For Vascular Rmentioning

confidence: 99%

Mesenchymal stem cells and vascular regeneration

Hong

Potter

et al. 2017

Microcirculation

View full text Add to dashboard Cite

In recent years, MSCs have emerged as a promising therapeutic cell type in regenerative medicine. They hold great promise for treating cardiovascular diseases, such as myocardial infarction and limb ischemia. MSCs may be utilized in both cell-based therapy and vascular graft engineering to restore vascular function, thereby providing therapeutic benefits to patients. The efficacy of MSCs lies in their multipotent differentiation ability toward vascular smooth muscle cells, endothelial cells and other cell types, as well as their capacity to secrete various trophic factors, which are potent in promoting angiogenesis, inhibiting apoptosis and modulating immunoreaction.Increasing our understanding of the mechanisms of MSC involvement in vascular regeneration will be beneficial in boosting present therapeutic approaches and developing novel ones to treat cardiovascular diseases. In this review, we aim to summarize current progress in characterizing the in vivo identity of MSCs, to discuss mechanisms involved in cell-based therapy utilizing MSCs, and to explore current and future strategies for vascular regeneration. K E Y W O R D Sangiogenesis, mesenchymal stem cells, stem cell-based therapy, vascular regeneration

show abstract

Section: Animal Studies and Clinical Trials Using Mscs For Vascular Rmentioning

confidence: 99%

Mesenchymal stem cells and vascular regeneration

Hong

Potter

et al. 2017

Microcirculation

View full text Add to dashboard Cite

show abstract

“…The functional activity of EPC is usually hypothesized to be based on either their physical incorporation into blood vessels and differentiation into EC and/or the release of proangiogenic factors stimulating neovascularization in a paracrine way (Madonna & De Caterina, ). Importantly, it is yet unknown what population of progenitor cells might have the most significant therapeutic potential in humans (Botham, Bennett, & Cooke, ). Clinical trials implementing the use of EPC were reviewed in more detail by others (Balistreri et al, ; Chong et al, ; Mitchell, Fujisawa, Newby, Mills, & Cruden, ).…”

Section: Introductionmentioning

confidence: 99%

Fetal bovine serum-free culture of endothelial progenitor cells-progress and challenges

Bauman

Granja

Barrias

2018

J Tissue Eng Regen Med

View full text Add to dashboard Cite

Two decades after the first report on endothelial progenitor cells (EPC), their key role in postnatal vasculogenesis and vascular repair is well established. The therapeutic potential of EPC and their growing use in clinical trials calls for the development of more robust, reproducible, and safer methods for the in vitro expansion and maintenance of these cells. Despite many limitations associated with its usage, fetal bovine serum (FBS) is still widely applied as a cell culture supplement. Although different approaches aiming at establishing FBS-free culture have been developed for many cell types, adequate solutions for endothelial cells, and for EPC in particular, are still scarce, possibly due to the multiple challenges that have to be faced when culturing these cells. In this review, we provide a brief overview on the therapeutic relevance of EPC and critically analyse the available literature on FBS-free endothelial cell culture methods, including xeno-free, serum-free, and chemically defined systems.

show abstract

“…To date, over 50 cell-therapy trials are at clinical stages for treating CLI. Many trials involve injecting MSCs 49–53 or ECs (such as MarrowStim) 52,54,55 , but the cells could die from deprivation of oxygen and nutrients before they are able to assemble into vascular networks in vivo and anastomose with host vasculature. The use of therapeutic pre-vascularized organoids could overcome many of the issues associated with currently cell therapy trials in clinical trials to treat CLI.…”

Section: Discussionmentioning

confidence: 99%

Injectable therapeutic organoids using sacrificial hydrogels

Rossen

Anandakumaran

Nieden

et al. 2020

Preprint

View full text Add to dashboard Cite

AbstractOrganoids, by promoting self-organization of cells into native-like structures, are becoming widespread in drug-screening technologies, but have so far been used sparingly for cell therapy as current approaches for producing self-organized cell clusters lack scalability or reproducibility in size and cellular organization. We introduce a method of using hydrogels as sacrificial scaffolds, which allow cells to form self-organized clusters followed by gentle release, resulting in highly reproducible multicellular structures on a large scale. We demonstrated this strategy for endothelial cells and mesenchymal stem cells to self-organize into blood-vessel units, which were injected into mice using hypodermic needles, and observed in real time to rapidly form perfusing vasculature. As cell therapy transforms into a new class of therapeutic modality, this simple method – by making use of the dynamic nature of hydrogels – could offer high yields of self-organized multicellular aggregates with reproducible sizes and cellular architectures.

show abstract

Clinical Trials of Adult Stem Cell Therapy for Peripheral Artery Disease

Cited by 32 publications

References 34 publications

Mesenchymal stem cells and vascular regeneration

Mesenchymal stem cells and vascular regeneration

Fetal bovine serum-free culture of endothelial progenitor cells-progress and challenges

Injectable therapeutic organoids using sacrificial hydrogels

Contact Info

Product

Resources

About